148: Navigating Transition: Supporting Young Adults With Epilepsy Into Adult Care

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, "Navigating Transition: Supporting Young Adults With Epilepsy Into Adult Care," Danielle Andrade, MD, MSc, adult neurologist at the University of Toronto and co-chair of the ILAE Transition Task Force, discussed the critical process of moving pediatric patients with epilepsy into adult care. She highlighted findings from the task force’s global survey on transition practices, revealing major differences across regions. Andrade also shared important considerations for students with epilepsy entering college, including lifestyle management and the “perfect storm” of seizure triggers like sleep deprivation, alcohol, and medication adherence. She spoke on the vital role of reproductive health discussions, the utility of readiness questionnaires, and the challenges of coordinating multi-specialty care. Finally, Andrade underscored the importance of clear communication between pediatric and adult neurologists, as well as the need for stronger guidelines and education worldwide.


Looking for more Epilepsy discussion? Check out the NeurologyLive® Epilepsy clinical focus page.

Episode Breakdown:

• 1:00 – Global survey findings on epilepsy transition of care
• 2:10 – Key considerations for students with epilepsy entering college
• 3:50 – Ensuring continuity of care during transition into adulthood
• 5:45 – Neurology News Minute
• 7:30 – Common challenges and strategies to overcome them
• 9:30 – Final thoughts on back-to-school care and global survey insights

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• Ianalumab Meets Primary End Points in Phase 3 NEPTUNUS Trials of Sjögren’s Disease

• Praxis’ Vormatrigine Shows Significant Ability to Reduce Seizure Incidence in Phase 2 RADIANT Study

• FDA Denies Approval for Friedreich Ataxia Agent Vatiquinone, Citing More Efficacy Needed

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.